ArticleThe Lancet regional health. Southeast Asia2026

Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial.

Rattagan Kajeekul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.